This case report investigates the therapeutic efficacy of TELOXOME, a novel stem cell-derived biologic agent developed by Conti new medical INC. (Taipei, Taiwan), in the treatment of advanced femoral condyle chondromalacia refractory to conventional management. A 46-year-old male athlete, previously diagnosed with Grade IV chondromalacia and unresponsive to multiple intra-articular interventions including platelet-rich plasma (PRP) and hyaluronic acid (HA) injections, was selected for treatment. The patient received a series of three intra-articular TELOXOME injections over a treatment period spanning 1.5 years, with follow-up assessments conducted at defined intervals. Magnetic resonance imaging (MRI) was performed at baseline, six months after the second injection and two years following the sixth injection to evaluate cartilage regeneration and structural integrity. Serial MRI imaging revealed progressive improvement in cartilage morphology, with notable restoration of articular cartilage in the femoral trochlear groove and reduction in subchondral bone edema. Additionally, laboratory findings demonstrated a significant decrease in C-reactive protein (CRP) levels, suggesting a concurrent reduction in systemic and local inflammation. Clinically, the patient reported marked alleviation of pain and functional improvement. These findings indicate that TELOXOME may exert both regenerative and anti-inflammatory effects in severe chondromalacia, potentially addressing a major unmet need in patients unresponsive to standard therapeutic approaches. This case highlights TELOXOME as a promising candidate in regenerative orthopedics and underscores the importance of further controlled clinical trials to validate its safety, efficacy and long-term outcomes. TELOXOME may represent a viable and innovative strategy for the treatment of cartilage-related disorders such as chondromalacia and osteoarthritis, particularly in patients for whom conventional therapies have failed.